Biogen Idec, Inc.

M&A Transactions Summary

Bought

Biogen - Idec ($7,559.25 million)

Nov 2003

Conforma Therapeutics Corporation from Domain Associates, L.L.C ($250 million)

May 2006

Hemophilia Inc. from Alta Partners LP ($120 million)

Jan 2007

Rights to Pre-clinical Immunotherapy Programs from Neurimmune ($427.50 million)

Dec 2010

Remaining 50% in Biogen-Dompe from Dompe Pharmaceticals ($195.50)

Sept 2011

Stromedix, Inc. from Atlas Venture L.P. ($562.50 million)

Feb 2012

Rights to Tysabri from Elan Pharma International Ltd. ($3,249.00 million)

Feb 2013

Sold

Manufacturing Assets to Tanox Inc. ($5.50 million)

Jan 2005

Oceanside Manufacturing Facility to Genentech, Inc. ($408.00 million)

June 2005

Rights to Amevive (Alefacept) to Astellas Pharma US, Inc. ($60.00 million)

April 2006

Virdante Pharmaceuticals, Inc. to Momenta Pharmaceuticals, Inc. ($56.00 million)

Dec 2011

Intelikine, Inc. to Takeda America Holdings, Inc. ($310.00 million)

Dec 2011

Eclipse Therapeutics, Inc. to Bionomics Ltd. ($6.42 million)

Sept 2012

Private Placements

Probiodrug AG ($19.39 million)

Jan 2012

Regulus Therapeutics ($5.00 million)

Aug 2012